113 lines
50 KiB
Text
113 lines
50 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548239">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548239/?report=reader">
|
|
<meta name="ncbi_pagename" content="Proguanil - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Proguanil - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Progestins/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Promethazine/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Proguanil">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2017/02/03">
|
|
<meta name="citation_pmid" content="31643564">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548239/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Proguanil">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2017/02/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548239/">
|
|
<meta name="description" content="Proguanil is a biguanide derivative which is active against several protozoal species and is used in combination with atovaquone and chloroquine for the prevention and therapy of malaria. Proguanil has not been evaluated extensively as a single agent, but the combinations of proguanil with atovaquone or chloroquine have been used to treat malaria and have been linked to serum enzyme elevations during therapy and rare instances of clinically apparent acute liver injury.">
|
|
<meta name="og:title" content="Proguanil">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Proguanil is a biguanide derivative which is active against several protozoal species and is used in combination with atovaquone and chloroquine for the prevention and therapy of malaria. Proguanil has not been evaluated extensively as a single agent, but the combinations of proguanil with atovaquone or chloroquine have been used to treat malaria and have been linked to serum enzyme elevations during therapy and rare instances of clinically apparent acute liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548239/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Proguanil/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548239/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8EC8E37D7F040100000000001C001B.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548239/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Progestins/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Proguanil</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Promethazine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548239/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548239/&text=Proguanil"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548239/?report=classic">Switch to classic view</a><a href="/books/NBK548239/pdf/Bookshelf_NBK548239.pdf">PDF (115K)</a><a href="/books/NBK548239/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548239%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8EC8E37D7F040100000000001C001B.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548239_"><span class="title" itemprop="name">Proguanil</span></h1><p class="fm-aai"><a href="#_NBK548239_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Proguanil.OVERVIEW"><h2 id="_Proguanil_OVERVIEW_">OVERVIEW</h2><div id="Proguanil.Introduction"><h3>Introduction</h3><p>Proguanil is a biguanide derivative which is active against several protozoal species and is used in combination with atovaquone and chloroquine for the prevention and therapy of malaria. Proguanil has not been evaluated extensively as a single agent, but the combinations of proguanil with atovaquone or chloroquine have been used to treat malaria and have been linked to serum enzyme elevations during therapy and rare instances of clinically apparent acute liver injury.</p></div><div id="Proguanil.Background"><h3>Background</h3><p>Proguanil (proe gwahn' il) is a biguanide which is metabolized by the liver to cycloguanil which has potent antimalarial activity. Cycloguanil appears to act by inhibition of plasmodial dihydrofolate reductase-thymidine synthetase and thereby interfering with folate metabolism and DNA synthesis in a manner somewhat similar to pyrimethamine. In contrast, atovaquone is a naphthoquinone that acts by binding to the protozoal or parasitic DNA and preventing DNA and RNA production and subsequent protein synthesis. The two agents are synergistic in combination and demonstrate no cross resistance. The combination of atovaquone and proguanil has been extensively evaluated and was approved in the United States in 2000 for the prevention and treatment of malaria, particularly for drug resistant P. falciparum infection. This combination is available in tablets that contain 250 mg of atovaquone and 100 mg of proguanil in several generic forms and under the brand name Malarone. The recommended therapeutic regimen is four tablets daily for 3 days and one tablet daily for prophylaxis. Combinations of proguanil with chloroquine have also been used in both treatment and prevention of malaria, but not in the United States. Specific and detailed recommendations on the therapy and prevention of malaria are available at: http://www.cdc.gov/malaria/. Common side effects of atovaquone/proguanil include diarrhea, anorexia, nausea, vomiting, abdominal discomfort, headache, dizziness, vivid dreams, insomnia and oral ulcers.</p></div><div id="Proguanil.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>The combination of atovaquone and proguanil has been associated with transient and minor serum aminotransferase elevations in a small proportion of patients. More importantly, there have been rare reports of idiosyncratic acute liver injury due in patients on atovaquone/ proguanil but the number of cases has been too few to define a typical clinical course. In one reported case, the onset of injury was after 3 weeks and presentation was with fatigue and jaundice and a cholestatic pattern of serum enzyme elevations. The injury resolved within 2 months of stopping the medication (Case 1). In another case report of chloroquine and proguanil, liver injury arose within days of starting the combination and the pattern of serum enzyme elevations was mixed. In both cases, allergic features were minimal and autoantibodies were not present. In both cases, combination therapy was used and either agent may have been the cause of the injury. Atovaquone and proguanil have also been linked to rare instances of Stevens Johnson syndrome which is often accompanied by mild liver injury or liver enzyme elevations.</p><p>Likelihood score: E* (unproven but sometimes suspected cause of clinically apparent liver injury).</p></div><div id="Proguanil.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which proguanil might cause liver injury is unknown. Proguanil is extensively metabolized by the liver. A toxic or immunologic reaction to an intermediate metabolite may underlie hepatotoxicity.</p></div><div id="Proguanil.Outcome_and_Management"><h3>Outcome and Management</h3><p>There does not seem to be cross reactivity to hepatic injury among the various antimalarial agents and switching to other drug can be done.</p><p>Drug Class: <a href="/books/n/livertox/AntimalarialAgents/?report=reader">Antimalarial Agents</a></p></div></div><div id="Proguanil.CASE_REPORT"><h2 id="_Proguanil_CASE_REPORT_">CASE REPORT</h2><div id="Proguanil.Case_1._Cholestatic_hepatitis_"><h3>Case 1. Cholestatic hepatitis after course of atovaquone/proguanil for malaria prophylaxis.</h3><p>[Modified from: Grieshaber M, Lämmli J, Marcus L. Acute hepatitis and atovaquone/proguanil. J Travel Med 2005; 12: 289-90. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16256055" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed Citation</a>]</p><p>A 31 year old man developed jaundice and abdominal pain a few days after a 25 day course of atovaquone (250 mg) and proguanil (100 mg) for malaria prophylaxis during travel. Other symptoms included poor appetite, itching, fatigue and dark urine. He had no previous history of liver disease or exposures to hepatitis and did not abuse alcohol. On examination, he had mild fever (37.5 <sup>o</sup>C) and was jaundiced. There was no mention of rash or eosinophilia. Serum bilirubin was mildly elevated at 2.9 mg/dL and both ALT and alkaline phosphatase levels were prominently increased (Table). Tests for viral hepatitis A, B, C and E were negative as were autoantibody markers. MRI of the abdomen showed a normal appearing liver and biliary system. A liver biopsy was not done. His symptoms gradually improved and serum enzyme abnormalities eventually resolved approximately 8 weeks after initial presentation.</p><div id="Proguanil.Key_Points"><h4>Key Points</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figProguanilT1"><a href="/books/NBK548239/table/Proguanil.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figProguanilT1" rid-ob="figobProguanilT1"><img class="small-thumb" src="/books/NBK548239/table/Proguanil.T1/?report=thumb" src-large="/books/NBK548239/table/Proguanil.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Proguanil.T1"><a href="/books/NBK548239/table/Proguanil.T1/?report=objectonly" target="object" rid-ob="figobProguanilT1">Table</a></h4></div></div></div><div id="Proguanil.Laboratory_Values"><h4>Laboratory Values</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figProguanilT2"><a href="/books/NBK548239/table/Proguanil.T2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figProguanilT2" rid-ob="figobProguanilT2"><img class="small-thumb" src="/books/NBK548239/table/Proguanil.T2/?report=thumb" src-large="/books/NBK548239/table/Proguanil.T2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Proguanil.T2"><a href="/books/NBK548239/table/Proguanil.T2/?report=objectonly" target="object" rid-ob="figobProguanilT2">Table</a></h4></div></div><p>* Estimated from Figure 1.</p></div><div id="Proguanil.Comment"><h4>Comment</h4><p>A case of cholestatic hepatitis typical of drug induced liver injury, and the only medications being used were atovaquone and proguanil, either of which may have been the cause. The somewhat delayed decline in serum enzymes is typical of cholestatic forms of drug induced liver injury.</p></div></div></div><div id="Proguanil.PRODUCT_INFORMATION"><h2 id="_Proguanil_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Proguanil.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Proguanil – Generic, Malarone® (with Atovaquone), Paludrine®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antimalarial Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Proguanil" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Proguanil.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Proguanil_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figProguanilT3"><a href="/books/NBK548239/table/Proguanil.T3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figProguanilT3" rid-ob="figobProguanilT3"><img class="small-thumb" src="/books/NBK548239/table/Proguanil.T3/?report=thumb" src-large="/books/NBK548239/table/Proguanil.T3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Proguanil.T3"><a href="/books/NBK548239/table/Proguanil.T3/?report=objectonly" target="object" rid-ob="figobProguanilT3">Table</a></h4></div></div></div><div id="Proguanil.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Proguanil_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 03 February 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Proguanil.R1">Zimmerman HJ. Antiprotozoal agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 623-5.<div><i>(Expert review of hepatotoxicity published in 1999; proguanil is not discussed).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R2">Vinetz JM, Clain J, Bounkeua V, Eastman RT, Fidock D. Chemotherapy of malaria.l In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman.s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1383-418.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R3">Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, et al. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. Br Med J (Clin Res Ed) 1988; 296: 820-2. [<a href="/pmc/articles/PMC2545106/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2545106</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3130927" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3130927</span></a>]<div><i>(Controlled trial of chloroquine with proguanil vs sulfadoxine-pyrimethamine is 767 travelers to Africa; similar efficacy and side effects; no mention of hepatic adverse events).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R4">Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: a postal and telephone survey of travelers. BMJ 1996; 313: 525-8. [<a href="/pmc/articles/PMC2351944/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2351944</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8789977" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8789977</span></a>]<div><i>(Mail questionnaire of 3851 British travelers taking either mefloquine or chloroquine/proguanil for malaria prophylaxis; the rate of side effects was similar [~41%], no mention of hepatic adverse events).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R5">Høgh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Günther M, Joubert I, et al.; Malarone International Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000; 356: 1888-94. [<a href="https://pubmed.ncbi.nlm.nih.gov/11130385" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11130385</span></a>]<div><i>(Controlled trial of atovaquone vs chloroquine combined with proguanil as malaria prophylaxis in 1008 travelers; efficacy was similar, but gastrointestinal upset was more common with chloroquine [20% vs 12%]; among 180 with laboratory testing “No clinically important laboratory abnormalities were identified”).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R6">Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, et al. Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015-21. [<a href="https://pubmed.ncbi.nlm.nih.gov/11528574" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11528574</span></a>]<div><i>(Controlled trial of atovaquone-proguanil vs mefloquine of malaria prophylaxis in 483 travelers; similar efficacy [100%], but neuropsychiatric side effects were more common with mefloquine [29% vs 14%] including insomnia, anxiety, vivid dreams, dizziness and trouble concentrating; no mention of liver injury and ALT levels were not monitored).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R7">Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27: 25-61. [<a href="https://pubmed.ncbi.nlm.nih.gov/14720085" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14720085</span></a>]<div><i>(Review of the toxicities and side effects of antimalarials; atovaquone/proguanil can cause minor ALT elevations, but clinically apparent liver injury was not mentioned).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R8">Camus D, Djossou F, Schilthuis HJ, Høgh B, Dutoit E, Malvy D, Roskell NS, et al.; International Malarone Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004; 38: 1716-23. [<a href="https://pubmed.ncbi.nlm.nih.gov/15227617" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15227617</span></a>]<div><i>(Controlled trial of atovaquone vs chloroquine combined with proguanil as malaria prophylaxis in 221 children; efficacy was similar [100%], but side effects slightly more with chloroquine [mostly gastrointestinal]; no mention of liver disease or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R9">Grieshaber M, Lämmli J, Marcus L. Acute hepatitis and atovaquone/proguanil. J Travel Med 2005; 12: 289-90. [<a href="https://pubmed.ncbi.nlm.nih.gov/16256055" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16256055</span></a>]<div><i>(31 year old man developed jaundice and abdominal pain 25 days after starting atovaquone/proguanil prophylaxis [bilirubin 2.9 mg/dL, ALT 320 U/L, Alk P 445 U/L], resolving slowly within 8 weeks of stopping: Case 1).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R10">Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 2005; 3: 849-61. [<a href="https://pubmed.ncbi.nlm.nih.gov/16307498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16307498</span></a>]<div><i>(Review of chemistry, clinical results and safety of atovaquone/proguanil; well tolerated and ALT elevations not discussed).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R11">Wielgo-Polanin R, Lagarce L, Gautron E, Diquet B, Lainé-Cessac P. Hepatotoxicity associated with the use of a fixed combination of chloroquine and proguanil. Int J Antimicrob Agents 2005; 26: 176-8. [<a href="https://pubmed.ncbi.nlm.nih.gov/16009537" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16009537</span></a>]<div><i>(50 year old woman developed jaundice 4 days after starting chloroquine/proguanil for prophylaxis [bilirubin 3.6 mg/dL, ALT 600 U/L, Alk P 744 U/L], resolving within 1 month of stopping; patient had a history of previous exposures to both agents).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R12">Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Vélez R, Paul M, et al; European Society for Clinical Microbiology and Infectious Diseases Study Group on Clinical Parasitology. Management of imported malaria in Europe. Malar J 2012;11: 328. [<a href="/pmc/articles/PMC3489857/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3489857</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22985344" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22985344</span></a>]<div><i>(Recommendations on treatment of malaria from a European panel; atovaquone-proguanil is a first line treatment for uncomplicated P. falciparum malaria; ALT elevations and hepatotoxicity are not mentioned).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R13">Kimura M, Koga M, Kikuchi T, Miura T, Maruyama H. Efficacy and safety of atovaquone-proguanil in treating imported malaria in Japan: the second report from the research group. Parasitol Int 2012; 61: 466-9. [<a href="https://pubmed.ncbi.nlm.nih.gov/22484597" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22484597</span></a>]<div><i>(30 cases of P. falciparum or vivax malaria in Japan were treated successfully with atovaquone-proguanil; one patient with P. falciparum had abnormal liver tests [bilirubin 2.0 mg/dL, ALT 294 U/L] with thrombocytopenia [48,000/μL] that resolved within 4 weeks of treatment).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R14">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9. [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to an antimalarial agent).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R15">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. (In a. [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>population based study from Iceland, 96 cases of drug induced liver injury were identified over a 2 year period [2010 and 2011], but none were attributed to an antimalarial agent).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R16">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to an antimalarial agentl).</i></div></div></li><li><div class="bk_ref" id="Proguanil.R17">Advice for travelers. Treat Guidel Med Lett 2015: 57 (1466): 52-8. <div><i>(Concise guidelines on prevention of malaria in travelers indicates that atovaquone-proguanil taken once daily is an effective prophylaxis against choloroquine resistant Plasmodium species, "...generally the best tolerated prophylactic, but it can cause headache, insomnia, GI disturbances and mouth ulcers, and is expensive. Single case reports of Stevens Johnson syndrome and hepatitis have been published").</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548239_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">February 3, 2017</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Proguanil. [Updated 2017 Feb 3].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Progestins/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Promethazine/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobProguanilT1"><div id="Proguanil.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548239/table/Proguanil.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Proguanil.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Atovaquone and proguanil</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Cholestatic (R=1.7)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">2+ (jaundice, not hospitalized)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Latency:</td><td rowspan="1" colspan="1" style="vertical-align:top;">25 days</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobProguanilT2"><div id="Proguanil.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548239/table/Proguanil.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Proguanil.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">ALT*<br /> (U/L)</th><th id="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P*<br /> (U/L)</th><th id="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Bilirubin* (mg/dL)</th><th id="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1 week</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">320</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">445</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.9</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">LDH 610 U/L</td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">330</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">410</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.2</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">710</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">330</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">310</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">240</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">280</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">190</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">75</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">115</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">60</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">110</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">105</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Proguanil.T2_1_1_1_1 hd_h_Proguanil.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">
|
|
<b>Normal Values</b>
|
|
</td><td headers="hd_h_Proguanil.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><40</b>
|
|
</td><td headers="hd_h_Proguanil.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><92</b>
|
|
</td><td headers="hd_h_Proguanil.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<b><1.2</b>
|
|
</td><td headers="hd_h_Proguanil.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="boxed-text" id="figobProguanilBPI"><div id="Proguanil.BPI" class="box boxed-text-box whole_rhythm hide-overflow"><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Proguanil – Generic, Malarone® (with Atovaquone), Paludrine®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antimalarial Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Proguanil" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></article><article data-type="table-wrap" id="figobProguanilT3"><div id="Proguanil.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548239/table/Proguanil.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Proguanil.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Proguanil.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Proguanil.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Proguanil.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Proguanil.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Proguanil.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Proguanil</td><td headers="hd_h_Proguanil.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">500-92-5</td><td headers="hd_h_Proguanil.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C11-H16-Cl-N5</td><td headers="hd_h_Proguanil.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548239/bin/Proguanil_Structure.jpg" alt="Chemical Structure for Proguanil" /></div>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|